TNFRSF18 and neoplasm: Finally, the combination of EphA2 ADCs with immunotherapies such as PD-L1 inhibitors and agonists of the glucocorticoid induced TNF receptor-related protein (GITR) in the CT26 model resulted in dramatic anti-tumour responses once again lending credence to potential for effective synergy.